In light of these properties and its GLP‐1 activity in regulating insulin secretion, in 2005, exendin‐4 (marketed as exenatide) became the first peptide approved by the FDA for the treatment of type II diabetes (Davidson et al. 2005). This evidence concerns the gene INS and type 2 diabetes mellitus.